Adenosine: An endogenous regulator of innate immunity

Trends in Immunology

Volumn 25, Issue 1, 2004, Pages 33-39

  Haskó, György ^a,b   Cronstein, Bruce N ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; AUTACOID; CAFFEINE; G PROTEIN COUPLED RECEPTOR; METHOTREXATE; PURINE NUCLEOSIDE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BIOAVAILABILITY; CELL DAMAGE; CELL FUNCTION; CELL TRANSPORT; DESTRUCTION; DRUG EFFECT; ENDOTHELIUM; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; ISCHEMIA; MAST CELL; METABOLITE; MOLECULAR RECOGNITION; NEUTROPHIL; NONHUMAN; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRESS; TISSUE INJURY;

EID: 0348222661     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2003.11.003     Document Type: Review

References (64)

1. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
2. Fredholm B.B., et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:2001;527-552.
3. Drury A.N., Szent-Györgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. 68:1929;213-237.
4. Newby A.C. Adenosine and the concept of retaliatory metabolites. Trends Biochem. Sci. 9:1984;42-44.
5. Pastor-Anglada M., et al. Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Mol. Membr. Biol. 18:2001;81-85.
6. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76:1994;5-13.
7. Sperlagh B., et al. Ischemic-like condition releases norepinephrine and purines from different sources in superfused rat spleen strips. J. Neuroimmunol. 111:2000;45-54.
8. Martin C., et al. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit. Care Med. 28:2000;3198-3202.
9. Sottofattori E., et al. HPLC determination of adenosine in human synovial fluid. J. Pharm. Biomed. Anal. 24:2001;1143-1146.
10. Di Virgilio F., et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood. 97:2001;587-600.
11. Haskó G., et al. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J. Immunol. 164:2000;1013-1019.
12. Scott G.S., et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc. Natl. Acad. Sci. U. S. A. 99:2002;16303-16308.
13. Montesinos M.C., et al. Wound healing is accelerated by agonists of adenosine A2 (G α s-linked) receptors. J. Exp. Med. 186:1997;1615-1620.
14. Feoktistov I., et al. Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ. Res. 90:2002;531-538.
15. Lennon P.F., et al. Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J. Exp. Med. 188:1998;1433-1443.
16. Eltzschig H.K., et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J. Exp. Med. 198:2003;783-796.
17. Bouma M.G., et al. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am. J. Physiol. 270:1996;C522-C529.
18. Cronstein B.N., et al. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J. Exp. Med. 158:1983;1160-1177.
19. Flamand N., et al. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am. J. Respir. Crit. Care Med. 161:2000;S88-S94.
20. 2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J. Infect. Dis. 180:1999;1550-1560.
21. 2A receptors promotes fMLP-induced cyclic AMP accumulation in human neutrophils: impact on phospholipase D activity and recruitment of small GTPases to membranes. J. Leukoc. Biol. 71:2002;367-377.
22. Rose F.R., et al. Adenosine promotes neutrophil chemotaxis. J. Exp. Med. 167:1988;1186-1194.
23. Wakai A., et al. Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation. Shock. 15:2001;297-301.
24. Bouma M.G., et al. Adenosine inhibits neutrophil degranulation in activated human whole blood; involvement of adenosine A2 and A3 receptors. J. Immunol. 158:1997;5400-5408.
25. Gessi S., et al. A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol. Pharmacol. 61:2002;415-424.
26. Janeway C.A. Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20:2002;197-216.
27. 3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur. J. Pharmacol. 358:1998;261-268.
28. 2A receptor-dependent and independent mechanisms. FASEB J. 14:2000;2065-2074.
29. 2A receptors inhibits IL-12 production by human monocytes. J. Immunol. 164:2000;436-442.
30. 2A receptors in human monocytic THP-1 cells. J. Immunol. 167:2001;4026-4032.
31. Haskó G., et al. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157:1996;4634-4640.
32. Sajjadi F.G., et al. Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J. Immunol. 156:1996;3435-3442.
33. 2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann. Neurol. 49:2001;727-735.
34. Szabó C., et al. Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. 125:1998;379-387.
35. 2A receptors. Am. J. Pathol. 163:2003;711-721.
36. Németh Z.H., et al. cDNA microarray analysis reveals a NF-κB-independent regulation of macrophage function by adenosine. J. Pharmacol. Exp. Ther. 306:2003;1042-1049.
37. Majumdar S., Aggarwal B.B. Adenosine suppresses activation of nuclear factor-κB selectively induced by tumor necrosis factor in different cell types. Oncogene. 22:2003;1206-1218.
38. 3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275:2000;4429-4434.
39. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920.
40. Xaus J., et al. IFN-γ up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J. Immunol. 162:1999;3607-3614.
41. Panther E., et al. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 15:2001;1963-1970.
42. Fossetta J., et al. Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Mol. Pharmacol. 63:2003;342-350.
43. Panther E., et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood. 101:2003;3985-3990.
44. Feger F., et al. The role of mast cells in host defense and their subversion by bacterial pathogens. Trends Immunol. 23:2002;151-158.
45. Ramkumar V., et al. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 268:1993;16887-16890.
46. Hannon J.P., et al. A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat. Br. J. Pharmacol. 115:1995;945-952.
47. Jin X., et al. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J. Clin. Invest. 100:1997;2849-2857.
48. Feoktistov I., et al. Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ. Res. 92:2003;485-492.
49. Smith S.R., et al. A role for histamine in cytokine modulation by the adenosine A(3) receptor agonist, 2-Cl-IB-MECA. Eur. J. Pharmacol. 457:2002;57-69.
50. Blackburn M.R., et al. Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J. Exp. Med. 192:2000;159-170.
51. Chunn J.L., et al. Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J. Immunol. 167:2001;4676-4685.
52. Blackburn M.R., et al. Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. J. Clin. Invest. 112:2003;332-344.
53. Blackburn M.R. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol. Sci. 24:2003;66-70.
54. Lawrence T., et al. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2:2002;787-795.
55. Bathon J.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343:2000;1586-1593.
56. Cronstein B.N., et al. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. U. S. A. 88:1991;2441-2445.
57. Cronstein B.N., et al. The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92:1993;2675-2682.
58. 2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48:2003;240-247.
59. Montesinos C., et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine. Evidence that the anti-inflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43:2000;656-663.
60. Nesher G., et al. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum. 48:2003;571-572.
61. Silke C., et al. The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology (Oxford). 40:2001;34.
62. Gadangi P., et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 156:1996;1937-1941.
63. Hwang K.K., et al. FK506 promotes adenosine release from endothelial cells via inhibition of adenosine kinase. Eur. J. Pharmacol. 425:2001;85-93.
64. Haskó G., et al. Adenosine: a potential mediator of immunosuppression in multiple organ failure. Curr. Opin. Pharmacol. 2:2002;440-444.